NASDAQ:BPTH - Bio-Path Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.74 +0.02 (+1.16 %)
(As of 05/25/2018 02:31 PM ET)
Previous Close$1.74
Today's Range$1.73 - $1.74
52-Week Range$1.53 - $5.85
Volume1,200 shs
Average Volume46,536 shs
Market Capitalization$19.73 million
P/E Ratio-2.15
Dividend YieldN/A
Beta2.73

About Bio-Path (NASDAQ:BPTH)

Bio-Path logoBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer. The company is also developing Liposomal Bcl2, which is in Phase I clinical trial for the treatment of lymphoma. It has license agreement with The University of Texas relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Receive BPTH News and Ratings via Email

Sign-up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BPTH
CUSIPN/A
Phone832-742-1357

Debt

Debt-to-Equity RatioN/A
Current Ratio6.38
Quick Ratio6.38

Price-To-Earnings

Trailing P/E Ratio-2.15
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$40,000.00
Price / Sales493.29
Cash FlowN/A
Price / CashN/A
Book Value$0.55 per share
Price / Book3.16

Profitability

EPS (Most Recent Fiscal Year)($0.80)
Net Income$-7,020,000.00
Net MarginsN/A
Return on Equity-109.22%
Return on Assets-98.99%

Miscellaneous

Employees9
Outstanding Shares11,340,000

Bio-Path (NASDAQ:BPTH) Frequently Asked Questions

What is Bio-Path's stock symbol?

Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."

When did Bio-Path's stock split? How did Bio-Path's stock split work?

Bio-Path shares reverse split on the morning of Thursday, February 8th 2018. The 1-10 reverse split was announced on Friday, February 9th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 9th 2018. An investor that had 100 shares of Bio-Path stock prior to the reverse split would have 10 shares after the split.

How were Bio-Path's earnings last quarter?

Bio-Path Holdings (NASDAQ:BPTH) issued its quarterly earnings data on Wednesday, May, 16th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.03. View Bio-Path's Earnings History.

When is Bio-Path's next earnings date?

Bio-Path is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Bio-Path.

What price target have analysts set for BPTH?

1 analysts have issued 12 month target prices for Bio-Path's stock. Their predictions range from $15.00 to $15.00. On average, they expect Bio-Path's stock price to reach $15.00 in the next twelve months. View Analyst Ratings for Bio-Path.

Who are some of Bio-Path's key competitors?

Who are Bio-Path's key executives?

Bio-Path's management team includes the folowing people:
  • Mr. Peter H. Nielsen, Co-Founder, Chairman, CEO, Pres, CFO & Treasurer (Age 69)
  • Mr. Douglas P. Morris, Co-Founder, Director of Investor Relations, Sec. & Director (Age 62)
  • Mr. Anthony Price MBA, Director of Fin. and Accounting
  • Dr. Ana Tari Ashizawa Ph.D., MBA, Director of Research
  • Dr. Suzanne Kennedy Ph.D., Director of Corp. Devel.

Has Bio-Path been receiving favorable news coverage?

Headlines about BPTH stock have been trending somewhat negative on Friday, Accern reports. Accern identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bio-Path earned a media sentiment score of -0.03 on Accern's scale. They also gave media coverage about the company an impact score of 47.09 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Bio-Path's major shareholders?

Bio-Path's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include University of Texas Texas AM Investment Managment Co. (3.38%). View Institutional Ownership Trends for Bio-Path.

Which institutional investors are selling Bio-Path stock?

BPTH stock was sold by a variety of institutional investors in the last quarter, including University of Texas Texas AM Investment Managment Co.. View Insider Buying and Selling for Bio-Path.

How do I buy shares of Bio-Path?

Shares of BPTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio-Path's stock price today?

One share of BPTH stock can currently be purchased for approximately $1.74.

How big of a company is Bio-Path?

Bio-Path has a market capitalization of $19.73 million and generates $40,000.00 in revenue each year. The company earns $-7,020,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Bio-Path employs 9 workers across the globe.

How can I contact Bio-Path?

Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The company can be reached via phone at 832-742-1357 or via email at [email protected]


MarketBeat Community Rating for Bio-Path (BPTH)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  165 (Vote Outperform)
Underperform Votes:  129 (Vote Underperform)
Total Votes:  294
MarketBeat's community ratings are surveys of what our community members think about Bio-Path and other stocks. Vote "Outperform" if you believe BPTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPTH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Bio-Path (NASDAQ:BPTH) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Bio-Path in the last 12 months. Their average twelve-month price target is $15.00, suggesting that the stock has a possible upside of 762.07%. The high price target for BPTH is $15.00 and the low price target for BPTH is $15.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $15.00$15.00$17.50$17.50
Price Target Upside: 762.07% upside383.87% upside464.52% upside464.52% upside

Bio-Path (NASDAQ:BPTH) Consensus Price Target History

Price Target History for Bio-Path (NASDAQ:BPTH)

Bio-Path (NASDAQ:BPTH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/13/2017HC WainwrightReiterated RatingBuy ➝ Buy$45.00 ➝ $15.00N/AView Rating Details
4/5/2017Maxim GroupSet Price TargetBuy$20.00HighView Rating Details
8/11/2016Rodman & RenshawSet Price TargetBuy$50.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Bio-Path (NASDAQ:BPTH) Earnings History and Estimates Chart

Earnings by Quarter for Bio-Path (NASDAQ:BPTH)

Bio-Path (NASDAQ BPTH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2018N/AView Earnings Details
5/16/2018Q1 2018($0.20)($0.17)ViewListenView Earnings Details
11/9/2017Q3 2017($0.20)($0.20)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.20)($0.30)ViewListenView Earnings Details
5/11/2017Q1 2017($0.20)($0.10)ViewN/AView Earnings Details
3/15/201712/31/2016($0.30)($0.10)$0.01 millionViewListenView Earnings Details
11/9/2016Q316($0.20)($0.20)$2.50 millionViewListenView Earnings Details
8/9/2016Q2($0.20)($0.20)ViewN/AView Earnings Details
5/11/2016Q1($0.10)($0.20)$2.33 millionViewListenView Earnings Details
3/16/2016Q4($0.10)($0.20)$1.46 millionViewN/AView Earnings Details
11/10/2015Q315($0.20)ViewN/AView Earnings Details
8/11/2015Q2 2015($0.30)($0.10)ViewN/AView Earnings Details
5/12/2015Q1 2015($0.20)ViewN/AView Earnings Details
3/17/2015Q4 2014$0.10($0.20)ViewN/AView Earnings Details
11/17/2014Q3 2014($0.10)($0.10)ViewN/AView Earnings Details
8/18/2014Q214($0.10)($0.10)ViewN/AView Earnings Details
5/16/2014Q1 2014($0.10)($0.10)ViewN/AView Earnings Details
4/2/2014$0.10$0.10ViewN/AView Earnings Details
11/15/2013Q3 2013($0.10)($0.20)ViewN/AView Earnings Details
8/15/2013Q2 2013($0.10)($0.10)ViewN/AView Earnings Details
5/16/2013Q1 2013($0.10)($0.10)ViewN/AView Earnings Details
11/16/2012Q3 2012($0.10)($0.10)ViewN/AView Earnings Details
8/16/2012Q2 2012($0.10)($0.10)ViewN/AView Earnings Details
5/17/2012Q1 2012($0.10)($0.10)ViewN/AView Earnings Details
4/3/2012Q4 2011($0.10)ViewN/AView Earnings Details
11/15/2011Q3 2011($0.20)($0.10)ViewN/AView Earnings Details
8/15/2011Q2 2011($0.10)($0.10)ViewN/AView Earnings Details
5/17/2011Q1 2011($0.20)($0.10)ViewN/AView Earnings Details
3/31/2011Q4 2010($0.10)($0.10)ViewN/AView Earnings Details
11/15/2010Q3 2010($0.10)ViewN/AView Earnings Details
8/17/2010Q2 2010($0.10)ViewN/AView Earnings Details
4/3/2009Q4 2008($0.50)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Bio-Path (NASDAQ:BPTH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Bio-Path (NASDAQ BPTH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.20%
Institutional Ownership Percentage: 9.48%
Insider Trading History for Bio-Path (NASDAQ:BPTH)
Institutional Ownership by Quarter for Bio-Path (NASDAQ:BPTH)

Bio-Path (NASDAQ BPTH) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/13/2015Michael J GarrisonDirectorBuy7,343$1.22$8,958.46View SEC Filing  
7/9/2015Michael J GarrisonDirectorBuy8,724$1.17$10,207.08View SEC Filing  
7/8/2015Michael J GarrisonDirectorBuy60,000$1.19$71,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Bio-Path (NASDAQ BPTH) News Headlines

Source:
DateHeadline
Bio-Path (BPTH) Announces Quarterly  Earnings Results, Beats Expectations By $0.03 EPSBio-Path (BPTH) Announces Quarterly Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - May 17 at 10:29 AM
Bio-Path Holdings Reports First Quarter 2018 Financial ResultsBio-Path Holdings Reports First Quarter 2018 Financial Results
globenewswire.com - May 16 at 10:36 AM
With A -19.42% Earnings Drop, Is Bio-Path Holdings Inc’s (NASDAQ:BPTH) A Concern?With A -19.42% Earnings Drop, Is Bio-Path Holdings Inc’s (NASDAQ:BPTH) A Concern?
finance.yahoo.com - May 16 at 10:36 AM
Bio-Path (BPTH) to Release Quarterly Earnings on WednesdayBio-Path (BPTH) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 12 at 8:51 PM
Bio-Path Holdings Appoints Dr. Anas Younes to Scientific Advisory BoardBio-Path Holdings Appoints Dr. Anas Younes to Scientific Advisory Board
finance.yahoo.com - May 10 at 10:06 AM
Bio-Path Holdings to Announce First Quarter 2018 Financial Results on May 16, 2018Bio-Path Holdings to Announce First Quarter 2018 Financial Results on May 16, 2018
finance.yahoo.com - May 9 at 9:55 AM
Bio-Path (BPTH) Stock Rating Upgraded by ValuEngineBio-Path (BPTH) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 3 at 10:05 PM
 Analysts Set $20.00 Price Target for Bio-Path Holdings (BPTH) Analysts Set $20.00 Price Target for Bio-Path Holdings (BPTH)
www.americanbankingnews.com - April 28 at 1:18 AM
Bio-Path (BPTH) Receives Buy Rating from HC WainwrightBio-Path (BPTH) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - April 19 at 11:20 PM
Mid-Day Market Update: Sears Hometown and Outlet Stores Falls Following Q4 Results; Bio-Path Shares SurgeMid-Day Market Update: Sears Hometown and Outlet Stores Falls Following Q4 Results; Bio-Path Shares Surge
www.benzinga.com - April 19 at 4:13 PM
Form 8-K BIO-PATH HOLDINGS INC For: Apr 18Form 8-K BIO-PATH HOLDINGS INC For: Apr 18
www.streetinsider.com - April 19 at 10:08 AM
Pre-Clinical Data Demonstrating Promising Potential of Prexigebersen as Treatment for Solid Tumors in Gynecologic ...Pre-Clinical Data Demonstrating Promising Potential of Prexigebersen as Treatment for Solid Tumors in Gynecologic ...
www.globenewswire.com - April 18 at 4:07 PM
Pre-Clinical Data Demonstrating Promising Potential of Prexigebersen as Treatment for Solid Tumors in Gynecologic Malignancies Presented at American Association for Cancer Research Annual MeetingPre-Clinical Data Demonstrating Promising Potential of Prexigebersen as Treatment for Solid Tumors in Gynecologic Malignancies Presented at American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 18 at 4:07 PM
Mid-Day Market Update: Dow Gains Over 200 Points; Enphase Energy Shares PlungeMid-Day Market Update: Dow Gains Over 200 Points; Enphase Energy Shares Plunge
www.nasdaq.com - April 3 at 4:12 PM
Bio-Path Holdings (BPTH) CEO Peter Nielsen on Q4 2017 Results - Earnings Call TranscriptBio-Path Holdings' (BPTH) CEO Peter Nielsen on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - April 3 at 4:12 PM
Bio-Path: Why the Biotech Penny Stock Is Skyrocketing TodayBio-Path: Why the Biotech Penny Stock Is Skyrocketing Today
investorplace.com - April 3 at 12:15 PM
ETF Report: ETFs, Futures Open in Positive Territory, Higher As Trade War Fears SubsideETF Report: ETFs, Futures Open in Positive Territory, Higher As Trade War Fears Subside
www.nasdaq.com - April 3 at 10:18 AM
US Stocks Poised for Rebound After Big SelloffUS Stocks Poised for Rebound After Big Selloff
www.nasdaq.com - April 3 at 10:18 AM
Bio-Path Holdings Announces Publication in The Lancet HaematologyBio-Path Holdings Announces Publication in The Lancet Haematology
finance.yahoo.com - March 29 at 10:30 AM
Bio-Path (BPTH) Lifted to "Sell" at ValuEngineBio-Path (BPTH) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - March 25 at 8:10 PM
Bio-Path Holdings to Present Data at the 2018 AACR Annual MeetingBio-Path Holdings to Present Data at the 2018 AACR Annual Meeting
finance.yahoo.com - March 15 at 10:52 AM
Bio-Path Holdings to Present at the 30th Annual ROTH ConferenceBio-Path Holdings to Present at the 30th Annual ROTH Conference
finance.yahoo.com - March 6 at 10:18 AM
Bio-Path (BPTH) to Release Quarterly Earnings on TuesdayBio-Path (BPTH) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - March 6 at 2:14 AM
 Brokerages Anticipate Bio-Path Holdings Inc (BPTH) to Announce -$0.20 Earnings Per Share Brokerages Anticipate Bio-Path Holdings Inc (BPTH) to Announce -$0.20 Earnings Per Share
www.americanbankingnews.com - February 14 at 1:08 AM
Bio-Path Holdings Inc (BPTH) Sees Large Decrease in Short InterestBio-Path Holdings Inc (BPTH) Sees Large Decrease in Short Interest
www.americanbankingnews.com - February 11 at 1:52 AM
Bio-Path Holdings (BPTH) Announces 1-for-10 Reverse Stock SplitBio-Path Holdings (BPTH) Announces 1-for-10 Reverse Stock Split
www.streetinsider.com - February 10 at 6:07 AM
Bio-Path Holdings Announces 1-for-10 Reverse Stock Split - GlobeNewswire (press release)Bio-Path Holdings Announces 1-for-10 Reverse Stock Split - GlobeNewswire (press release)
globenewswire.com - February 9 at 3:27 PM
Bio-Path Holdings to Present at the BIO CEO & Investor ConferenceBio-Path Holdings to Present at the BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 5:52 AM
Bio-Path Holdings Appoints Paul Aubert to its Board of Directors - GlobeNewswire (press release)Bio-Path Holdings Appoints Paul Aubert to its Board of Directors - GlobeNewswire (press release)
globenewswire.com - February 5 at 3:20 PM
Bio-Path Holdings Appoints Paul Aubert to its Board of DirectorsBio-Path Holdings Appoints Paul Aubert to its Board of Directors
finance.yahoo.com - February 5 at 3:20 PM
Pre-Market Technical Scan on Drug Delivery Equities -- Bio-Path, Alkermes, PetMed Express, and Valeant Pharma - PR Newswire (press release)Pre-Market Technical Scan on Drug Delivery Equities -- Bio-Path, Alkermes, PetMed Express, and Valeant Pharma - PR Newswire (press release)
www.prnewswire.com - February 1 at 3:20 PM
Analyzing Merrimack Pharmaceuticals (MACK) & Bio-Path (BPTH)Analyzing Merrimack Pharmaceuticals (MACK) & Bio-Path (BPTH)
www.americanbankingnews.com - January 25 at 3:14 PM
Form 8-K BIO-PATH HOLDINGS INC For: Dec 29 - StreetInsider.comForm 8-K BIO-PATH HOLDINGS INC For: Dec 29 - StreetInsider.com
www.streetinsider.com - January 3 at 12:03 AM
HC Wainwright Reaffirms "Buy" Rating for Bio-Path (BPTH)HC Wainwright Reaffirms "Buy" Rating for Bio-Path (BPTH)
www.americanbankingnews.com - December 31 at 3:38 PM
Bio-Path Holdings Provides Clinical Update and 2018 Business OutlookBio-Path Holdings Provides Clinical Update and 2018 Business Outlook
finance.yahoo.com - December 29 at 5:27 PM
-$0.02 Earnings Per Share Expected for Bio-Path Holdings, Inc. (BPTH) This Quarter-$0.02 Earnings Per Share Expected for Bio-Path Holdings, Inc. (BPTH) This Quarter
www.americanbankingnews.com - December 25 at 1:16 PM
Financial Comparison: Bio-Path (BPTH) & Brainstorm Cell Therapeutics (BCLI)Financial Comparison: Bio-Path (BPTH) & Brainstorm Cell Therapeutics (BCLI)
www.americanbankingnews.com - November 27 at 5:22 PM
 Analysts Anticipate Bio-Path Holdings, Inc. (BPTH) Will Post Earnings of -$0.02 Per Share Analysts Anticipate Bio-Path Holdings, Inc. (BPTH) Will Post Earnings of -$0.02 Per Share
www.americanbankingnews.com - November 20 at 1:28 AM
Bio-Path Holdings, Inc. (BPTH) Given New $1.50 Price Target at Bio-Path Holdings, Inc. (BPTH) Given New $1.50 Price Target at
www.americanbankingnews.com - November 19 at 4:20 PM
Bio-Path Holdings, Inc. (BPTH) Releases Quarterly  Earnings Results, Hits EstimatesBio-Path Holdings, Inc. (BPTH) Releases Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - November 10 at 12:51 PM
Bio-Path Holdings Inc (BPTH): How Does It Impact Your Portfolio?Bio-Path Holdings Inc (BPTH): How Does It Impact Your Portfolio?
finance.yahoo.com - November 10 at 12:41 PM
Bio-Path Holdings Reports Third Quarter 2017 Financial ResultsBio-Path Holdings Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 5:52 PM
Bio-Path reports 3Q lossBio-Path reports 3Q loss
finance.yahoo.com - November 9 at 5:52 PM
Bio-Path Holdings Highlights Advancements in Preclinical Discovery Efforts - GlobeNewswire (press release)Bio-Path Holdings Highlights Advancements in Preclinical Discovery Efforts - GlobeNewswire (press release)
globenewswire.com - November 9 at 12:29 AM
Bio-Path Holdings Highlights Advancements in Preclinical Discovery EffortsBio-Path Holdings Highlights Advancements in Preclinical Discovery Efforts
finance.yahoo.com - November 6 at 5:51 PM
Bio-Path Holdings (BPTH) Announces $4M Registered Direct Offering of Common Stock and WarrantsBio-Path Holdings (BPTH) Announces $4M Registered Direct Offering of Common Stock and Warrants
www.streetinsider.com - November 3 at 5:20 PM
Bio-Path Holdings, Inc. Announces $4 Million Registered Direct OfferingBio-Path Holdings, Inc. Announces $4 Million Registered Direct Offering
finance.yahoo.com - November 3 at 5:20 PM
Bio-Path Holdings to Announce Third Quarter 2017 Financial Results on November 10, 2017Bio-Path Holdings to Announce Third Quarter 2017 Financial Results on November 10, 2017
finance.yahoo.com - November 3 at 8:25 AM
Bio-Path Holdings, Inc. (BPTH) Scheduled to Post Quarterly Earnings on WednesdayBio-Path Holdings, Inc. (BPTH) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 1 at 4:06 AM
Bio-Path Holdings (BPTH) and Palatin Technologies (PTN) Financial ComparisonBio-Path Holdings (BPTH) and Palatin Technologies (PTN) Financial Comparison
www.americanbankingnews.com - October 30 at 9:28 AM

SEC Filings

Bio-Path (NASDAQ:BPTH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Bio-Path (NASDAQ:BPTH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Bio-Path (NASDAQ BPTH) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.